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1. Introduction 
It is well known that GABA plays an inhibitory role 
in crustacean ans mammalian central nervous system 
[ 1,2]. Since GABA does not cross the blood-brain 
barrier, various inhibitors of GABA aminotransferase 
which cause an increase in its cerebral level have been 
introduced into this field of research [3-121. Most of 
these inhibitors are very toxic and not specific for 
GABA aminotransferase. 
During our search for new inhibitors of GABA 
aminotransferase from microbial origin, a potent 
inhibitor (designated as gabaculine) was found to be 
present in the culture of a Streptomyces. The present 
paper describes isolation and inhibitory activity of 
gabaculine. The results indicate that this new micro- 
bial metabolite is a potent, competitive inhibitor of 
GABA aminotransferase from both beef brain and 
Pseudomonas ovalis, having Ki values of 0.37-0.80 PM. 
The physicochemical properties and identification 
of chemical structure of gabaculine have been reported 
elsewhere [13]. 
2. Materials and methods 
2 .I. Chemicals 
All chemicals used were of the purest grade commer- 
cially available. 
Abbreviations: GABA r-aminobutyric acid, GABA amino- 
transferase 4-aminobutyrate-2-oxoglutarate minotransferase 
(EC 2.6.1.19) 
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2.2. Enzyme preparations 
Beef brain mitochondria and cytosolic fraction were 
prepared from fresh cerebrum by the method of 
Waksman et al. [14]. Cell-free extracts, used as a bacte- 
rial GABA aminotransferase, were obtained from 
Pseudomonas ovalis as described by Jakoby [ 151. For 
routine experiments, beef brain mitochondria were 
used as enzyme. Protein was determined by the method 
of Lowry et al. [16]. 
2.3. Enzyme assay 
The reaction mixture (1 .O ml) contained: 50 mM 
a-ketoglutarate, 100 mM GABA, 0.57 mM pyridoxal 
phosphate, 100 mM Tris-HCl, pH 8.0 and 1’0-15 mg 
protein of beef brain mitochondria or 20-30 pg 
protein of Ps. ovalis cell-free extracts. After incubation 
of 37’C for 180 min for the former enzyme or 60 min 
for the latter, the reaction was terminated by addition 
of 0.3 ml 10% sulfuric acid and 0.3 ml 5% sodium 
tungstate, and glutamate formed was determined by 
using Leuconostoc mesenteroides ATCC 9135 by the 
method of Tamura et al. [17]. 
2.4. Streptomyces strain 
The strain of Streptomyces employed in the 
production of gabaculine, which was isolated from a 
soil from Tohoku District in Japan, was found to be 
closely related to Streptomyces toyocaensis and 
designated as St. toyocaensis No. 1039 according to 
Shirling and Gottlieb [18,19]. 
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3. Results and discussion 
3.1. Isolation of gabaculine 
Streptomyces toyocaensis No. 1039 was grown 
aerobically in a medium containing 2% soluble starch, 
1% glucose, 1.5% Pharmamedia (Traders Oil Mill Co. 
USA), 2% corn steep liquor (Corn Products Co. USA) 
and 1% Lab-Lemco beef extract (Oxoid Ltd, England) 
in a 50-l fermentor for 96 h at 27°C. To the culture 
filtrate (21 liters), 1% of active carbon (Wako Pure 
Chemical, Japan) was added, at pH 2.5 and after 
stirring for 30 min the mixture was filtered. The 
resulting filtrate was adjusted to pH 7.0 with sodium 
hydroxide and applied to a column (12 X 7 1 cm) of 
Diaion SK-1B (H form) (Nippon Rensui, Japan). The 
column was washed with 17 liters water and then 
eluted with 0.5 N ammonium hydroxide. The active 
eluate (30 liters) was concentrated to 900 ml under 
reduced pressure and then added to 8 liters 80% 
methanol. The precipitate formed was removed by 
filtration. The filtrate was concentrated to 110 ml 
under reduced pressure, adjusted to pH 4.0 with 
acetic acid and then applied to a column (3 X 35 cm) 
of Amberlite IR-120 (H form) (Rohm and Haas USA) 
equilibrated with 0.2 M sodium acetate buffer, pH 4.0. 
The column was eluted with 4 liters 0.2 M sodium 
acetate buffer, pH 4.2 and then with 0.2 M sodium 
acetate buffer, pH 4.5. The eluate containing gaba- 
culine (15.6 liters) was evaporated to dryness under 
reduced pressure, yielding 8.1 g of brownish powder. 
This powder was submitted to chromatography in a 
cellulose column (10 X 65 cm) equilibrated with 
n-butanollwater (100:7). The column was developed 
with the same solvent and the active eluate (21.5 
liters) was concentrated to 150 ml under reduced 
pressure. The resulting precipitate was collected by 
filtration, dissolved in a small volume of water and 
then lyophilized, giving 102 mg purified gabaculine. 
The purified gabaculine was homogeneous as 
judged by thin-layer chromatography on silica-gel plates 
(60F-254, E. Merck) in ethanol/concentrated ammonia/ 
water (6:2: 1) (Rf 0.65) and on cellulose plates (F, E. 
Merck) in n-butanollacetic acid/water (3: 1: 1) (RF 0.53). 
3.2. Inhibitory activity 
As shown in fig.1, gabaculine was inhibitory to 
GABA aminotransferase from two sources, beef brain 
mitochondria and Ps. ovalis. Concentrations required 
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Fig. 1. Inhibition by gabaculine of GABA aminotransferase 
from beef brain and Aeudomonos ovolis. Enzyme activity 
was determined as described in Materials and methods. The 
values for control were 0.25 mmol/h/mg protein for brain 
enzyme and 0.40 mmol/h/mg protein for bacterial enzyme, 
respectively. (-•-) Beef brain mitochondrial enzyme. (-o-) 
A. ovolis enzyme. 
for 50% inhibition were 1.1 PM for beef brain mito- 
chondrial enzyme and 0.7 nM for Ps. ovalis enzyme, 
respectively. The enzyme contained in the cytosolic 
fraction of beef brain was also inhibited by gabaculine 
to a similar extent (data not shown). The inhibition was 
competitive with respect to GABA and uncompetitive 
with respect to a-ketoglutarate (figs 2 and 3). The Ki- 
values were calculated to be 0.80 PM for mitochondrial 
enzyme and 0.37 PM for bacterial enzyme, respectively. 
Under these conditions, Km-values for GABA and 
a-ketoglutarate were 21 mM and 5 mM with beef 
brain mitochondrial enzyme and 15 mM and 7.1 mM 
with bacterial enzyme, respectively. 
As shown above, gabaculine is a potent inhibitor 
of GABA aminotransferase. When administered syste- 
mically to mice at a dose of 50 mg/kg, gabaculine 
produces an increase of approximately 7-fold in brain 
GABA-level 8 h after administration [20], indicating 
that this compound is one of the metabolic inhibitors 
useful in the studies of physiological role of GABA in 
central nervous system mechanism. 
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Fig.2. Double reciprocal plots of the inhibition of GABA aminotransferase by gabaculine. Experiments were carried out as 
described in Materials and methods, except that concentrations of GABA (in A and B) and or-ketoglutarate (in C and D) were 
varied as indicated. Enzymes used were beef brain mitochondria in (A) and (C) and A. ovalis cell-free extracts in (B) and (D). 
(*) Control, (4) 0.25 PM gabaculine, (-o-) 0.5 PM gabaculine, (J-) 1.0 PM gabaculine. 
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